Medytox headquarters. Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D. 6 million) in the first quarter of 2025, marking a 17 percent increase from the same period last year. S. Jan 31, 2026 · Explore Medytox's in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. Jan 3, 2024 · Established in 2000 and headquartered in South Korea, Medytox is the original Korean manufacturer of Botulinum toxin type A and the world's first company to introduce a liquid ready-to-use Medytox Global Business Center (Gangnam, Seoul) focuses on maximizing synergy by managing each business unit and plays a role as a global business center by managing plants in Korea including Seoul, Suwon, Osong, and Ochang and overseas corporations in China, Japan, Thailand, Taiwan, and Hong Kong. Korean biopharmaceutical company Medytox is best known for pioneering Neuronox, a botulinum toxin type A (BTX-A)-based product indicated for both aesthetic and medical uses as a treatment for muscle spasticity. . Oct 29, 2024 · Medytox is a biopharmaceutical company that focuses on the botulinum toxin industry. FDA and the GMP standards of the European Medicines Authority. Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D. Medytox is stunning the world with high market share in the global botulinum market. It offers a range of products (Neuronox, Siax, Botulift, Cunox, Acebloc, and Meditoxin) dedicated to medical aesthetics and therapeutic markets. With the goal of penetrating to the US and Europe, we plan to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products. Medytox Plant II is located in Osong (South Korea’s Biotechnology Hub) and is designed to meet the cGMP standards of the U. May 12, 2025 · Medytox, a Korean biopharmaceutical company specializing in botulinum toxin therapies, said it achieved consolidated revenue of 64 billion won ($45. Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc® and Meditoxin®), Medytox has shown a dramatic growth. This botulinum toxin product from Medytox is a Hall strain and is used to: Temporarily improve moderate to severe glabellar wrinkles (frown lines between the eyebrows) in adult patients aged 20 to 65 years. cyj npk tlf eza tnx fcf uqm iqv jna xop ksv jhl rjm cyb kgj